Clinical Trials Browser

Interventional × Paraproteinemias × 90 days × Clear all

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Phase 1 Completed

50 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

NCT07075185 2026-04-24

inMMyCAR

Phase 1 Recruiting

70 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

281 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT03236428 2026-03-27

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

42 enrolled 8 charts

Plasma cell

Smoldering Multiple Myeloma, Paraproteinemias

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

120 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

125 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Clinical Trials

MGUS-PET

Rifaximin in Patients With Monoclonal Gammopathy

inMMyCAR

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

CLOVER-WaM

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)